Phase I dose escalation study to evaluate the safety and pharmacokinetic profile of tefibazumab in subjects with end-stage renal disease requiring hemodialysis

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 10, 2006, Pages 3499-3500

  Hetherington, Seth ^a,e   Texter, Michele ^a   Wenzel, Eric ^a   Patti, Joseph M ^a   Reynolds, Laurie ^b   Shamp, Trish ^c   Swan, Suzanne ^d  

^a Inhibitex Inc   (United States)

^b ICON Development Solutions   (United States)

^c Prism Research   (United States)

^d HENNEPIN COUNTY MEDICAL CENTER   (United States)

^e Icagen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; TEFIBAZUMAB; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BACKACHE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE EXACERBATION; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; EDEMA; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LEUKOPENIA; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; TACHYCARDIA; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADHESINS, BACTERIAL; ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 33749528964     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00407-06     Document Type: Article

References (10)

1. Domanski, P. J., P. R. Patel, A. S. Bayer, L. Zhang, A. E. Hall, P. J. Syribeys, E. L. Gorovits, D. Bryant, J. H. Vernachio, J. T. Hutchins, and J. M. Patti. 2005. Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus. Infect. Immun. 73:5229-5232.
2. Fowler, V. G., Jr., A. Justice, C. Moore, D. K. Benjamin, Jr., C. W. Woods, S. Campbell, L. B. Reller, G. R. Corey, N. P. Day, and S. J. Peacock. 2005. Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin. Infect. Dis. 40:695-703.
3. Friedman, N. D., K. S. Kaye, J. E. Stout, S. A. McGarry, S. L. Trivette, J. P. Briggs, W. Lamm, C. Clark, J. MacFarquhar, A. L. Walton, L. B. Reller, and D. J. Sexton. 2002. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann. Intern. Med. 137:791-797.
4. Leveque, D., S. Wisniewski, and F. Jehl. 2005. Pharmacokinetics of therapeutic monoclonal antibodies used in oncology. Anticancer Res. 25:2327-2343.
5. Lowy, F. D. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339:520-532.
6. McDevitt, D., P. Francois, P. Vaudaux, and T. J. Foster. 1994. Molecular characterization of the clumping factor (fibrinogen receptor) of Staphylococcus aureus. Mol. Microbiol. 11:237-248.
7. McDevitt, D., P. Vaudaux, and T. J. Foster. 1992. Genetic evidence that bound coagulase of Staphylococcus aureus is not clumping factor. Infect. Immun. 60:1514-1523.
8. Mire-Sluis, A. R., Y. C. Barrett, V. Devanarayan, E. Koren, H. Liu, M. Maia, T. Parish, G. Scott, G. Shankar, E. Shores, S. J. Swanson, G. Taniguchi, D. Wierda, and L. A. Zuckerman. 2004. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 289:1-16.
9. Morin, C. A., and J. L. Hadler. 2001. Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998. J. Infect. Dis. 184:1029-1034.
10. Reilley, S., E. Wenzel, L. Reynolds, B. Bennett, J. M. Patti, and S. Hetherington. 2005. Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers. Antimicrob. Agents Chemother. 49:959-962.